Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03449069 · ClinicalTrials.gov registry record · Phase 1
Pediatric MSC-AFP Sub-study for Crohn's Fistula
A Phase 1 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
NCT03449069: Completed Phase 1 study, sponsored by Mayo Clinic.
NCT03449069 is a Phase 1 study that has completed, run by Mayo Clinic. The registered enrollment target is 1 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03449069, a Phase 1 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety of using an autologous mesenchymal stromal cell (MSC) coated fistula plug in people with fistulizing Crohn's disease. Autologous means these cells to coat the plug come from the patient.
Primary Outcome
Participants will have a health assessment and blood work done at each study visit to monitor for adverse events.
Interventions
- DRUG MSC-AFP
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2018-07-23 |
| Est. Completion | 2023-12-31 |
| Phase | Phase 1 |
What the finished NCT03449069 record still lists
NCT03449069 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 1 intervention - of which MSC-AFP is the first listed.
NCT03449069 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03449069 about?
NCT03449069 is a clinical study titled "Pediatric MSC-AFP Sub-study for Crohn's Fistula". The purpose of this study is to determine the safety of using an autologous mesenchymal stromal cell (MSC) coated fistula plug in people with fistulizing Crohn's disease. Autologous means these cells to coat the plug come from the patient.
What is the current status of trial NCT03449069?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2018-07-23. Estimated completion is 2023-12-31.
What interventions are being tested in trial NCT03449069?
The interventions under investigation include: MSC-AFP (DRUG).
Who is sponsoring clinical trial NCT03449069?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03449069's enrollment target sits among peer trials
1 2001st of 2000 the lowest of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI